SavedAdd your journal

Journals / Nöropsikiyatri Arşivi / 2021 / Cilt: 58 - Sayı: 1

Pharmacotherapy of Schizophrenia in Acute and Maintenance Phase

Şizofreni Tedavisinde Akut Dönem ve Sürdürüm Döneminde İlaç Tedavisi

UMUT KIRLI
Köksal ALPTEKİN
Pages
17–23
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Finally, practical considerations will be suggested.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Schizophrenia is one of the leading disorders causing impairment in society.
📊
Key Findings & Data:Therefore, it is crucial to review evidence-based treatment approaches which are both effective and causing minimum side effects.
💡
Conclusion & Impact:Finally, practical considerations will be suggested.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Schizophrenia is one of the leading disorders causing impairment in society. Therefore, it is crucial to review evidence-based treatment approaches which are both effective and causing minimum side effects. In this paper, treatment recommendations for first episode schizophrenia, patients in acute phase with a history of multiple episodes, and patients in the maintenance phase will be discussed in light of the Psychiatric Association of Turkey Guideline for Treatment of Schizophrenia, other recent national and international guidelines as well as expert consensus reports in the literature. Finally, practical considerations will be suggested.

Özet

Şizofreni genel toplumda en sık yeti yitimine neden olan bozukluklardan birisidir. Bu nedenle şizofrenide en az yan etkiye neden olan etkin tedavi yaklaşımlarının kanıta dayalı olarak derlenmesi önemlidir. Bu yazıda şizofreninin ilk psikotik dönemi, önceden şizofreni tanısı konmuş kişilerde alevlenme dönemleri ve sürdürüm dönemi için tedavi önerileri tartışılacaktır. Konu üzerine Türkiye Psikiyatri Derneği Şizofreni Tedavi Kılavuzu ve diğer ulusal ve uluslararası güncel rehberlerde yer alan öneriler derlenecek ve pratik önerilerde bulunulacaktır.

🔖

Cite This Article

KIRLI, U., ALPTEKİN, K. (2021). Pharmacotherapy of Schizophrenia in Acute and Maintenance Phase. Nöropsikiyatri Arşivi, Cilt: 58 - Sayı: 1, 17–23. https://ajindex.com/articles/413521

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Binbay T, Ulas H, Elbi H, Alptekin K. The psychosis epidemiology in Turkey: a systematic review on prevalence estimates and admission rates. Turk Psikiyatri Derg 2011;22:40–52
  2. Binbay T, Alptekin K, Elbi H, Zagli N, Drukker M, Aksu Tanik F, Ozkinay F, Onay H, Van Os J. Lifetime prevalence and correlates of schizophrenia and disorders with psychotic symptoms in the general population of Izmir, Turkey. Turk Psikiyatri Derg 2012;23:149–160
  3. Binbay T, Arik Binbay D, Ulas H, Alptekin K. Admission-Based Prevalence of Schizophrenia, Schizoaffective Disorder and Bipolar I Disorder in a Catchment Area in Sinop, Turkey. Turk Psikiyatri Derg 2016;27:151–160
  4. Sağlık Bakanlığı. Türkiye Hastalık Yükü Çalışması 2004. Ankara: Türkiye Cumhuriyeti Sağlık Bakanlığı; 2006
  5. McGorry PD, Hartmann JA, Spooner R, Nelson B. Beyond the “at risk mental state” concept: transitioning to transdiagnostic psychiatry. World Psychiatry 2018;17:133–142
  6. Marder SR, Essock SM, Miller AL, Buchanan RW, Casey DE, Davis JM, Kane JM, Lieberman JA, Schooler NR, Covell N, Stroup S, Weissman EM, Wirshing DA, Hall CS, Pogach L, Pi-Sunyer X, Bigger JT, Friedman A, Kleinberg D, Yevich SJ, Davis B, Shon S. Physical Health Monitoring of Patients With Schizophrenia. Am J Psychiatry 2004;161:1334–1349
  7. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a metaanalysis. The Lancet 2009;373:31–41
  8. Robinson DG, Schooler NR, John M, Correll CU, Marcy P, Addington J, Brunette MF, Estroff SE, Mueser KT, Penn D, Robinson J, Rosenheck RA, Severe J, Goldstein A, Azrin S, Heinssen R, Kane JM. Prescription Practices in the Treatment of First-Episode Schizophrenia Spectrum Disorders: Data From the National RAISE-ETP Study. Am J Psychiatry 2015;172:237–248
  9. Gören JL, Parks JJ, Ghinassi FA, Milton CG, Oldham JM, Hernandez P, Chan J, Hermann RC. When Is Antipsychotic Polypharmacy Supported by Research Evidence? Implications for QI. Jt Comm J Qual Saf 2008;34:571–582
  10. Barbui C, Signoretti A, Mule S, Boso M, Cipriani A. Does the Addition of a Second Antipsychotic Drug Improve Clozapine Treatment? Schizophr Bull 2008;35:458–468
  11. Baandrup L. Polypharmacy in schizophrenia. Basic Clin Pharmacol 2020;126:183–192
  12. Turkiye Psikiyatri Dernegi Sizofreni ve Diger Psikotik Bozukluklar Calisma Birimi. Sizofrenide Genel Tedavi İlkeleri ve Akut Alevlenme Doneminde Tedavi. In: Ucok A, Soygur H, editors. Sizofreni Teda